Aeolus Pharmaceuticals Initiates Second Study For AEOL 10150

Aeolus Pharmaceuticals has initiated second study in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. The study is designed to build on study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.

AEOL 10150 has been safe and tolerated in two phase safety studies and in animal studies it is helpful in protecting the lungs from radiation damage and increasing survival at doses in the range of 5 to 30mg/kg given daily up to 24 hrs after irradiation and administered for as long as 10 weeks.

The compound mitigated functional lung injury in rats and led to a statistical survival advantage in mice. AEOL 10150 has proven to be an effective countermeasure to radiation exposure of the lungs in mice and rats.

John McManus, president and chief executive officer of Aeolus Pharmaceuticals, said: “The results of this study will be critical in helping us design the pivotal study in mice, which we expect will be one of the two species necessary for approval of AEOL 10150 as a countermeasure to nuclear threats under the US FDA’s Animal Rule.”